Audit: QRS - Whey Protein Isolate for Health & Longevity

Audit conducted on 11/08/2026 09:41 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated variable traces to an ER passage: protocol cells to ER Therapeutic Protocol (lines 388, 404, 414), time cells to Practical Considerations (line 455) and line 406, benefits/risks to the tier headings in Expected Benefits and Potential Risks & Side Effects, gates to Key Interactions & Contraindications, monitoring to the biomarker table (lines 489–500) and cadence prose (line 485).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No source section is empty and no cautious empty-state phrasing in the ER was overwritten with a stronger form.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“unless supervised by a nephrologist” → “without nephrologist supervision” and “Pregnancy and lactation, where evidence is absent…” → “Pregnancy and lactation” preserve gate strength; nothing is upgraded or downgraded.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid” list, Key Interactions only from the ER’s interaction bullets, and risks only from Potential Risks & Side Effects. No modifying factor is promoted into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, expert names, NCT identifiers, or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Flat, declarative, non-promotional register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and doses are paired with plain-language rationale in the sub-cells and the “Why” column.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as noun phrases and observed patterns, not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend”, “advise”, “consult”, or “avoid” appears in the QRS body.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and monitoring cells present values and rationale, not instructions.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns occur anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to decision gates and biomarker names, where precision is load-bearing; explanatory text is plain.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are stripped to key facts; monitoring “Why” cells are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for second-person forms.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional targets (ApoB below 80 mg/dL, fasting insulin below 6 µIU/mL, HbA1c below 5.4%) rather than conventional lab cutoffs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split 3–4 daily servings, concurrent resistance training, and a 12-marker panel presume high willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Nothing is simplified to a general-population “take a scoop” framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states benefit shrinks toward nothing where intake is already high or training is absent — the case that applies to much of this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity” and marker_9_why refers to “the longevity concern”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“postprandial hypotension”, “anabolic resistance”, “appendicular lean mass index”); the qualitative items are carried verbatim from ER lines 504–509.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte-for-byte (lines 446, 492, 541, 574, 596, 634, 665, 669–671, 848).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Set comparison against the template yields no missing variable; the repeatable marker_#_* and qualitative_item_# rows are expanded to 12 and 6 instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A normalized diff against the template shows differences only inside data-qrs-var spans and in the repeated table/list rows; the style block, website="evidence_review", website="audit", website="full_review" spans, and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section feeding the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standard supplemental dose”, action_2_label “Single versus split dosing”, action_3_label “Age-related adjustment” are the ER’s bold labels verbatim (ER lines 388, 404, 414); monitoring row labels are the ER biomarker column entries verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels are the subjects of the ER’s own “Time to effect” bullet (ER line 455); no label is invented.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode scan finds no emoji in the QRS; the ER’s tier emoji were dropped and replaced by the template’s CSS palette and bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than extended: 12 ER benefit/risk headings collapse to four tier lines each, interaction drug lists are trimmed to one or two named examples, and monitoring “Why” cells are cut to single clauses.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is duplicated into the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, and it contains a colon that requires quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: whey_protein_isolate_2026-0811-0627_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0811-0915.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the on-disk filename whey_protein_isolate_2026-0811-0627_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine keys parse cleanly; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Whey Protein Isolate for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Whey Protein Isolate for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/11/2026”, the MM/DD/YYYY form of 2026-0811-0915.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header contains only the title and the template’s fixed subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 531–533: strongest use, where benefit disappears, and the common harms.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Protein shortfall plus lifting, older/frail population, benefit shrinking at high intake, digestive upset and allergy, and the post-drink blood pressure fall past 65 each map to a separate clause of ER lines 531–533.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “fast-digesting milk protein”, “lifts weights”, “digestive upset”, “blood pressure falls” are all lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates; the only figure is the age threshold 65.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the “Populations who should avoid Whey Protein Isolate” list at ER lines 356–362.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span (lines 577–591).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale tails such as “given whey’s high phenylalanine content” and “where evidence is absent and heavy metal contamination cannot be excluded” are stripped; the only dash present is the range “stage 4–5”.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	eGFR below 30 mL/min/1.73m², Child-Pugh C, above age 75, and “any age, including adults tolerant of milk” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention -->	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items come from the interaction bullets at ER lines 330–352.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All twelve ER interactions are present; none duplicates an item in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Twelve <li> elements inside the caution_items span (lines 599–624).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic sentences (transporter competition, blunted heart-rate rise, chelation of residual calcium) are all stripped; no dashes appear in any item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Each item retains its named examples and its separation window where the ER gives one (1 hour for levodopa, 1 and 4 hours for levothyroxine/bisphosphonates, 2 hours for iron/antacids and for tetracyclines/fluoroquinolones); longer example lists are trimmed but never emptied.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names twelve interactions, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used -->	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol bullets at lines 388, 404, and 414.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dose distribution, and the age-65 adjustment are the three executable levers; the remaining ER bullets are positional debate, conflict-of-interest notes, kinetics, or genotype items with no dosing implication.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action variables carry ER-derived content; no placeholder remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Lean mass, blood pressure and lipids, and appetite/post-meal glucose are the three onset windows given in the ER’s “Time to effect” bullet (line 455).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Lean mass (High tier) first, blood pressure and lipids (Medium tier) second, appetite and post-meal glucose third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time variables carry ER-derived content; the glucose sub-cell reproduces the pre-meal pattern from ER line 406.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at line 455.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten items are the ER’s benefit sub-headings from lines 158–218.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated (lines 543–567).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the bare benefit names remain; the “in Overweight Adults” qualifier and the “⚠️ Conflicted” markers are dropped, and no magnitude figures are carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine items are the ER’s risk sub-headings from lines 246–306.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated (lines 636–659).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	“in Older Adults” and “with Chronic Excessive Intake” qualifiers are stripped; no frequencies or magnitudes carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence come from the ER Monitoring Protocol & Defining Success section (lines 485–500).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All twelve rows of the ER biomarker table are present in the same order, with targets reproduced faithfully.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 838–842 reproduce the ER’s schedule from line 485, including the 6-monthly kidney testing below eGFR 60.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	The six items come from the qualitative marker list at ER lines 504–509.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present, verbatim and in the same order.

Issues 11/08/2026 09:41

Pass rate 100.00%. No issues found.

Issues 11/08/2026 09:28

1. 4.5 — Sheet overruns one A4 page: The Key Interactions gate (lines 604–637), the Contraindications gate (lines 576–598), the Monitoring “Why” column (lines 695–846), and the cadence line (853–858) are carried at near-ER length rather than condensed, putting the sheet at roughly twice the single-page budget.

Fixes 11/08/2026 09:28

1. 4.5 — Key Interactions gate condensed: Trimmed the multi-drug example lists to the leading named agents and shortened the separation windows (e.g. the iron/antacid item from “ferrous sulfate, ferrous gluconate, calcium carbonate, aluminium-magnesium hydroxide; reduced absorption, separate two hours” to “ferrous sulfate, calcium carbonate; reduced absorption; separate 2 hours”), cutting the gate from 27 to 21 rendered lines while keeping every interaction and at least one example drug per item.
2. 4.5 — Contraindications gate condensed: Tightened all seven items (“Chronic kidney disease stage 4 or 5 … unless supervised by a nephrologist” → “stage 4–5 … without nephrologist supervision”; “Child-Pugh Class C” → “Child-Pugh C”), preserving every threshold, severity class, and age qualifier.
3. 4.5 — Monitoring “Why” column shortened: Reduced eight of the twelve rationale cells to single-line phrasing (e.g. “Reflects protein load and hydration; a rise without an eGFR fall usually means intake, not damage” → “Reflects protein load; a rise without an eGFR fall means intake, not damage”) and shortened the IGF-1 target to “Age-adjusted mid-normal, not upper quartile”.
4. 4.5 — Cadence line shortened: Compressed the monitoring cadence to “…grip strength at 12 weeks, then every 6 months; kidney markers annually, or 6-monthly if starting eGFR is below 60”, removing one rendered line.
5. 4.5 — Protocol sub-lines tightened: Shortened all three action sub-lines (e.g. “Sized to close the gap between habitual intake and a total protein target of 1.2–1.6 g per kilogram of body weight” → “Sized to close the gap to a total protein target of 1.2–1.6 g per kilogram of body weight”) to reclaim height in the hero panel.

Issues 11/08/2026 09:22

1. 1.1 / 1.3 — Blood pressure fall overstated as common: [at_a_glance] (QRS lines 437-438) reads “Digestive upset, allergy, and post-drink blood pressure drops are the common harms”, but the ER Conclusion (line 533) names only “Digestive upset and allergic reactions” as “the common ones” and restricts the blood pressure drop to something that “matters specifically for people past 65”; the ER also tiers the postprandial fall as Medium rather than High.

Fixes 11/08/2026 09:22

1. 1.1 / 1.3 — Blood pressure fall no longer called common: Rewrote the closing clause of [at_a_glance] from “Digestive upset, allergy, and post-drink blood pressure drops are the common harms.” to “Digestive upset and allergy are the common harms; blood pressure falls after large drinks matter past 65.”, restoring the ER’s age restriction and its separation of the common harms from the age-specific one. Trimmed “real” and “already” elsewhere in the paragraph to hold the total at the 60-word limit.